Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2
Authors:
- 1 January 2019
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 161, 445-455
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of China (81373279)
- Ministry of National Science and Technology (2012ZX09103101048)
This publication has 32 references indexed in Scilit:
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Combining Emerging Agents in Advanced Breast CancerThe Oncologist, 2011
- Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitorsEuropean Journal of Cancer, 2010
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Breast Cancer, Estrogen Receptor and LigandsArchiv der Pharmazie, 2009
- Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer PatientsClinical Cancer Research, 2009
- Designed Multiple Ligands. An Emerging Drug Discovery ParadigmJournal of Medicinal Chemistry, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Discovery of Novel Quinoline-Based Estrogen Receptor Ligands Using Peptide Interaction ProfilingJournal of Medicinal Chemistry, 2004
- Risk of endometrial cancer after tamoxifen treatment of breast cancerThe Lancet, 1994